{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:13:46Z","timestamp":1793776426691,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.isci.2024.109417","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T11:41:53Z","timestamp":1709552513000},"page":"109417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Lama","family":"Hasan Bou Issa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha","family":"Ouelkdite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Tilmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Brinster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Touil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Quesnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Kluza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.109417_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.109417_bib2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109417_bib3","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109417_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2024.109417_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2024.109417_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2024.109417_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2024.109417_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109417_bib9","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2024.109417_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180147","article-title":"Sequence-specific DNA binding by MYC\/MAX to low-affinity non-E-box motifs","volume":"12","author":"Allevato","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2024.109417_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","article-title":"The c-Myc target gene network","volume":"16","author":"Dang","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.isci.2024.109417_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2024.109417_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2967\/jnumed.110.084244","article-title":"Role of Glutamine in Cancer: Therapeutic and Imaging Implications: FIGURE 1","volume":"52","author":"Rajagopalan","year":"2011","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2024.109417_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2024.109417_bib15","doi-asserted-by":"crossref","first-page":"50754","DOI":"10.1074\/jbc.M408388200","article-title":"The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells","volume":"279","author":"Revollo","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2024.109417_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database Hallmark Gene Set Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.isci.2024.109417_bib17","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1093\/nar\/gkg794","article-title":"A role for c-Myc in the regulation of ribosomal RNA processing","volume":"31","author":"Schlosser","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2024.109417_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"Van Riggelen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2024.109417_bib19","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/sj.onc.1207548","article-title":"The role of c-myc in regulation of translation initiation","volume":"23","author":"Schmidt","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2024.109417_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2668","article-title":"Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma","volume":"9","author":"Manier","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2024.109417_bib21","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3390\/cancers13174484","article-title":"MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype","volume":"13","author":"Tambay","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2024.109417_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2008.05.005","article-title":"Regulation of glutathione synthesis","volume":"30","author":"Lu","year":"2009","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.isci.2024.109417_bib23","doi-asserted-by":"crossref","first-page":"13836","DOI":"10.1073\/pnas.1008366107","article-title":"Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109417_bib24","doi-asserted-by":"crossref","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109417_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2012.06.005","article-title":"The dynamic regulation of NAD metabolism in mitochondria","volume":"23","author":"Stein","year":"2012","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.isci.2024.109417_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.isci.2024.109417_bib27","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1038\/onc.2015.415","article-title":"NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer","volume":"35","author":"Hong","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2024.109417_bib28","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fonc.2019.01514","article-title":"Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy","volume":"9","author":"Heske","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2024.109417_bib29","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2024.109417_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \u201cundruggable\u201d MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2024.109417_bib31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40259-019-00370-5","article-title":"Mission Possible: Advances in MYC Therapeutic Targeting in Cancer","volume":"33","author":"Allen-Petersen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2024.109417_bib32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jcb.26264","article-title":"BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC","volume":"119","author":"Ba","year":"2018","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.isci.2024.109417_bib33","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1038\/s41388-022-02347-1","article-title":"Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer","volume":"41","author":"Constantin","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2024.109417_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","article-title":"Lin28 promotes transformation and is associated with advanced human malignancies","volume":"41","author":"Viswanathan","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2024.109417_bib35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.109417_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/nm.3952","article-title":"Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma","volume":"21","author":"Mazur","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2024.109417_bib37","doi-asserted-by":"crossref","first-page":"85858","DOI":"10.18632\/oncotarget.20691","article-title":"Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation","volume":"8","author":"Effenberger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2024.109417_bib38","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109417_bib39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109417_bib40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2024.109417_bib41","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-18-3527","article-title":"LKB1 and KEAP1\/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS -Mutant Lung Adenocarcinoma","volume":"79","author":"Galan-Cobo","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2024.109417_bib42","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109417_bib43","doi-asserted-by":"crossref","first-page":"79722","DOI":"10.18632\/oncotarget.12944","article-title":"Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes","volume":"7","author":"Matre","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2024.109417_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","article-title":"In\u00a0vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells","volume":"8","author":"Gonsalves","year":"2020","journal-title":"Cancer Metabol."},{"key":"10.1016\/j.isci.2024.109417_bib45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109417_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.27713","article-title":"Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition","volume":"6","author":"Muir","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.isci.2024.109417_bib47","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56749","article-title":"A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer","volume":"9","author":"Jin","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.isci.2024.109417_bib48","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28083","article-title":"Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer","volume":"6","author":"Sayin","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.isci.2024.109417_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","article-title":"The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell\u2013Mediated Immunotherapies","volume":"20","author":"Varghese","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2024.109417_bib50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ccell.2018.04.002","article-title":"The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma","volume":"33","author":"Momcilovic","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2024.109417_bib51","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2024.109417_bib52","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109417_bib53","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1158\/1535-7163.MCT-09-1130","article-title":"A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor","volume":"9","author":"Olesen","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2024.109417_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/auto.5635","article-title":"NAD depletion by FK866 induces autophagy","volume":"4","author":"Billington","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.isci.2024.109417_bib55","first-page":"313","article-title":"Chemopotentiating effects of a novel nad biosynthesis inhibitor, fk866, in combination with antineoplastic agents","volume":"11","author":"Pogrebniak","year":"2006","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.isci.2024.109417_bib56","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1074\/jbc.M112.394510","article-title":"Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells","volume":"288","author":"Tan","year":"2013","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224006382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224006382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:32:29Z","timestamp":1783384349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004224006382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2589004224006382"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.109417","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.109417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"109417"}}